- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Future of ePRO Platforms
It is tempting to imagine the use of the patient’s own mobile computing platform for collection of patient reported outcomes.
It is tempting to imagine the use of the patient’s own mobile computing platform for collection of patient reported outcomes. This would solve some of the problems faced when using the e-PRO devices employed today:
- Provisioning costs (purchasing or leasing the devices to be used in the trial)
- Supply issues (delivering the devices to the sites for distribution to subjects, and collection after the subject completes the trial)
- Training (handling and use of the device by subjects and site staff)
- Maintenance and Help Desk (device-related help desk questions, replacement of faulty devices)
Click here for an Applied Clinical Trials article by Alan Yeomans that evaluates the practicality of such an approach, and the issues that need to be addressed if it is to succeed.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
